Table 4.

Results from sensitivity analyses

	Ages 5–10 years (second-dose effect)			Ages 12–15 years (third-dose effect)
	Second dose confirmed infections (at-risk days), n	Internal control confirmed infections (at-risk days), n	Adjusted rate ratio internal control vs second dose (95% CI)	Third dose confirmed infections (at-risk days), n	Internal control confirmed infections (at-risk days), n	Adjusted rate ratio internal control vs third dose (95% CI)
Main analysis	576 (347 726)	743 (318 513)	2·3 (2·0–2·5)	166 (171 281)	494 (180 100)	3·3 (2·8–4·0)
All population groups	602 (366 364)	822 (367 168)	2·3 (2·1–2·6)	179 (178 780)	518 (190 139)	3·2 (2·7–3·8)
Longer study period	3142 (840 479)	1699 (430 094)	1·9 (1·8–2·0)	911 (410 853)	1379 (285 267)	2·9 (2·6–3·1)
Shorter study period	530 (286 144)	524 (148 127)	2·2 (2·0–2·5)	148 (120 433)	395 (103 922)	3·2 (2·7–3·9)
Matching	..	..	2·2 (2·0–2·4)	..	..	4·0 (3·5–4·5)

Results from sensitivity analyses including all population groups (general Jewish, ultra-orthodox Jewish, and Arab), longer (Dec 26, 2021, to Jan 15, 2022), and shorter (Jan 2, 2022, to Jan 8, 2022) study periods.